A detailed history of Spire Wealth Management transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Spire Wealth Management holds 447 shares of APLS stock, worth $15,434. This represents 0.0% of its overall portfolio holdings.

Number of Shares
447
Previous 16 2693.75%
Holding current value
$15,434
Previous $0 Infinity%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024

BUY
$28.84 - $41.15 $12,430 - $17,735
431 Added 2693.75%
447 $12,000
Q2 2024

Jul 31, 2024

SELL
$38.07 - $59.71 $266 - $417
-7 Reduced 30.43%
16 $0
Q1 2024

Apr 24, 2024

BUY
$55.39 - $72.47 $609 - $797
11 Added 91.67%
23 $1,000
Q4 2023

Feb 06, 2024

BUY
$37.14 - $64.82 $445 - $777
12 New
12 $0
Q2 2023

Aug 09, 2023

BUY
$76.68 - $93.31 $920 - $1,119
12 New
12 $1,000

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.79B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Spire Wealth Management Portfolio

Follow Spire Wealth Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Spire Wealth Management, based on Form 13F filings with the SEC.

News

Stay updated on Spire Wealth Management with notifications on news.